Patients with rare bone cancer still have low survival rates
the ONA take:
Mesenchymal chondrosarcoma remains classified among the more deadly cancer types, but a recent study has indicated that survival for this disease may not be as low as was previously thought.
A Loyola University Medical Center study, led by senior author Lukas Nystrom, MD, reviewed survival for 205 individuals with mesenchymal chondrosarcoma (cases occurring between 1973 and 2011).
Data was sourced from the Surveillance, Epidemiology and End Results (SEER) program database, which is administered through the National Cancer Institute (NCI). Fifty-one percent survived a minimum of 5 years, and 43 percent survived 10 years or more. survival rates observed differed, depending on the tumor location: an axial location demonstrated a lower survival rate.
Dr. Nystrom has suggested that this lower survival outcome could be attributable to the inoperable location of the axial tumors.
Improved screening techniques and technology could be a factor in the lowering (if still high) mortality rates overall.
Mesenchymal chondrosarcoma remains classified among the more deadly cancer types.
Sign Up for Free e-newsletters
- Evolution of HER2-Positive Breast Cancer: Yesterday, Today, and Tomorrow
- Scalp Cooling With Dignicap May Reduce Alopecia During Chemotherapy for Breast Cancer
- Dedicated End-of-Life Education Program Improves Nurses' Care, Patient and Family Satisfaction
- Oncology Extended Care Clinic Reduced Urgent Cancer-Related ED Visits
- Cervical Cancer Outcomes Comparable With Adjuvant Chemotherapy, Chemoradiotherapy
- Hair Dyes and Cancer Risk (Fact Sheet)
- Taste Changes After Hematopoietic Stem Cell Transplant Affect QOL in Blood Cancers
- Hope, Optimism Reduce Psychological Distress in Advanced Cancer
- Mitomycin Extravasation Protocol
- Risk for Long-Term Cardiovascular Disease Increased for Endometrial Cancer Survivors
- Nursing Practice Change Improved Chemo Administration, But Old Habits Die Hard
- Simple Adjustment Key to Paclitaxel Infusion Protocol That Reduced Hypersensitivity Reactions
- Online Program Aims to Assist With Clinical Trial Enrollment for Hematologic Cancers
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Skipping the SICU Post Head and Neck Cancer Surgery May Improve Outcomes
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|